Zuclopenthixol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Zuclopenthixol: From Schizophrenia to Retinal Dystrophy
One-Sentence Summary
Zuclopenthixol is a thioxanthene antipsychotic, originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia (from the knowledge graph; no approved indication text is available in the New Zealand licence record) |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| New Zealand Market Status | Cancelled only (no currently valid licence) |
| Number of Authorizations | 1 (cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, zuclopenthixol is a thioxanthene antipsychotic that acts mainly as a dopamine D1/D2 and 5-HT2A receptor antagonist. Its efficacy in schizophrenia comes from this receptor blockade.
For the predicted indication, no mechanistic link has been established. Inherited retinal dystrophies are genetically diverse, and nothing in the available data connects dopamine receptor antagonism to their pathophysiology. The TxGNN score (0.99994) is a graph-based prediction only. In addition, drugs in the related phenothiazine class are associated with retinal toxicity, which argues against benefit rather than for it.
Other top-ranked predictions show the same pattern: none has clinical or literature support.
| Rank | Predicted Disease | Score | Assessment |
|---|---|---|---|
| 2 | Hydranencephaly | 99.99% | Structural congenital brain malformation; no plausible link to dopamine antagonism |
| 3 | Congenital disorder of glycosylation with defective fucosylation | 99.99% | Glycan biosynthesis disorder; no known drug action on this pathway |
| 4 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 99.99% | Hereditary neuropathy; no link to myelin maintenance or repair |
| 5 | X-linked myopia | 99.99% | Retinal dopamine agonism, not antagonism, is considered protective against myopia, so the direction of effect is unfavourable |
| 6 | Perisylvian polymicrogyria with cerebellar hypoplasia and arthrogryposis | 99.99% | Congenital cortical malformation; no expected benefit |
| 7 | Syndromic myopia | 99.99% | Same unfavourable direction of effect as above |
| 8 | Myopia 26, X-linked, female-limited | 99.99% | Monogenic; no link to the underlying gene; antagonism unfavourable |
| 9 | Atypical glycine encephalopathy | 99.99% | Inborn error of glycine metabolism; no action on this pathway |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 390372 (cancelled) | Clopixol | Tab 10 mg | Not available |
Cytotoxicity
Not applicable. Zuclopenthixol is an antipsychotic, not an antineoplastic drug.
Safety Considerations
- Retinal toxicity concern: Phenothiazine-class antipsychotics are associated with retinal toxicity, which is particularly relevant when considering use in retinal disease.
- Drug Interactions: No interaction records were found in the data compiled for this report.
Please refer to the package insert for further safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a graph-model score. There are no clinical trials or publications, no plausible mechanism, and a theoretical safety concern (retinal toxicity). The only New Zealand licence is cancelled.
To proceed, the following is needed:
- Mechanistic evidence linking dopamine/5-HT receptor antagonism to inherited retinal dystrophy pathophysiology
- Preclinical or literature evidence in retinal disease models
- Package insert warnings and contraindications from Medsafe, to allow safety screening
- Confirmation of the original mechanism of action data from DrugBank
- Assessment of route and formulation suitability for retinal indications
- Clarification of current New Zealand availability, since the only licence is cancelled
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.